Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months Motley Fool - Fri Feb 16, 4:50AM CST

Analysts are quite bullish about these beaten-down stocks.

SLB : 49.67 (+1.95%)
BABA : 75.27 (-1.66%)
RPRX : 28.14 (-0.67%)
Why PTC Therapeutics Soared 15% Higher Today Motley Fool - Thu Oct 19, 2023

The company scored a $1 billion upfront payment for expanding a commercial partnership.

PTCT : 32.63 (-0.55%)
RPRX : 28.14 (-0.67%)
2 Dividend Stocks Wall Street Thinks Can Rise by 50% Motley Fool - Wed Jul 26, 2023

These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit.

RPRX : 28.14 (-0.67%)
JD : 26.26 (-0.08%)
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million Business Wire - Thu Mar 23, 2023

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, and Royalty...

PRTC : 22.10 (-1.78%)
PRTC.LN : 170.000 (+2.16%)
RPRX : 28.14 (-0.67%)
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness PR Newswire - Mon Jan 9, 2023

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired an interest...

IONS : 47.82 (+1.04%)
RPRX : 28.14 (-0.67%)
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen Business Wire - Tue Dec 20, 2022

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of...

ARWR : 28.30 (+2.39%)
AMGN : 331.29 (+0.10%)
RPRX : 28.14 (-0.67%)
6 Stocks Warren Buffett Completely Exited in 2022 Motley Fool - Sat Dec 17, 2022

Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio.

BRK.AX : 0.012 (unch)
BRK.A : 652,040.00 (-1.63%)
BRK.B : 434.47 (-1.66%)
BRK-A : N/A (N/A)
BRK-B : N/A (N/A)
VZ : 41.62 (-1.07%)
STOR : 32.21 (unch)
ABBV : 172.32 (+0.69%)
RPRX : 28.14 (-0.67%)
BMY : 42.64 (+0.59%)
WFC : 59.23 (-0.02%)
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones Business Wire - Wed Nov 9, 2022

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million...

ARWR : 28.30 (+2.39%)
RPRX : 28.14 (-0.67%)
Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer PR Newswire - Mon Nov 7, 2022

Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35%...

RPRX : 28.14 (-0.67%)
TBPH : 9.57 (-1.14%)
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position Motley Fool - Tue Oct 18, 2022

There may be more trouble on the horizon for these stocks than most investors are seeing right now.

DE : 378.06 (-0.68%)
RPRX : 28.14 (-0.67%)
ERIE : 377.34 (-1.02%)

Barchart Exclusives

Stocks Set to Open Higher After Biden’s Withdrawal, Earnings and Key U.S. Inflation Data in Focus Barchart - 46 minutes ago
September S&P 500 E-Mini futures (ESU24) are up +0.47%, and September Nasdaq 100 E-Mini futures (NQU24) are up +0.59% this morning as investors looked past Joe Biden’s exit from his presidential reelection campaign and awaited a slew of corporate earnings reports, with a particular focus on results from “Magnificent Seven” companies Tesla and Alphabet, as well as the release of the Fed’s preferred inflation gauge later in the week. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot